ECTRIMS 2022: Dimethyl Fumarate Demonstrates Benefit in People With Radiologically Isolated Syndrome
Treatment with dimethyl fumarate tied to 80 percent reduction in risk for first clinical event related to central nervous system demyelination
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.